In addition to PDL1, EBVaGCs express higher levels of CD155/PVR, CEACAM1, and galectin-9 mRNAs (Figure 5), which represent known anti-tumor immunity genes that antagonize T cell responses. The gene discussed is LGALS9; the disease is neoplasm.